One way archaeologists learn how ancient people, including Neanderthals, did things is to attempt to do those things themselves, a process called experimental archaeology. Normally, that involves making stone tools, butchering deer, or distilling birch tar. But in a new study, it meant doing very destructive things to teeth from one of the world’s most carefully protected animals.

That's because the archeologists suspected that Neanderthals once used rhino teeth as tools. By using the teeth to make stone tools, the researchers demonstrated that Neanderthals probably did the same thing, adding to what we know about the wide range of items in their toolkits.

We need to hit some rhino teeth with rocks for science

Some Neanderthal archaeological sites in Europe and Asia seem to have many more rhinoceros teeth lying around than you’d expect. We know Neanderthals hunted a now-extinct species of rhinoceros in Europe and eastern Asia, but the people who had inhabited these sites looked like they had been collecting rhino teeth for some reason.

Read full article

Comments

© By Bernard DUPONT from FRANCE - White Rhino Skull, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=55453022

In December, the Trump administration abruptly announced it would shut down the National Center for Atmospheric Research (NCAR), a Boulder, Colorado-based facility that helps researchers perform studies of weather, climate, atmospheric chemistry, and more. The news came as a shock, given that the government had never identified serious deficiencies in the management of NCAR and its associated supercomputing center in Wyoming.

Nevertheless, the government ordered the University Consortium for Atmospheric Research (UCAR), which manages NCAR on behalf of the National Science Foundation, to help it prepare to transfer the Wyoming facility to a different operator. UCAR sued the government and, on Monday, won a preliminary injunction that places the transfer of the facility on hold.

Is that your final decision?

NCAR is what is termed a "Federally-Funded Research and Development Center" meant to support researchers in the academic community. Rather than having its own research agenda, it provides facilities, equipment, and expertise to support projects that are too large or complex for researchers to pursue on their own. NCAR has been around since the early 1960s and has become a critical resource for the global atmospheric science community.

Read full article

Comments

© Matthew Jonas/MediaNews Group/Boulder Daily Camera via Getty Images

Tom Holland talked about the connections between his two big blockbusters releasing in July.

The good news: When environmental rules pressure one company, the effect can spread through shared boardroom ties, leading connected firms to reduce emissions, too.

The good news: When environmental rules pressure one company, the effect can spread through shared boardroom ties, leading connected firms to reduce emissions, too.

In a significant advance in biological quantum sensing, a research team led by the Technical University of Munich (TUM) has discovered and tested a new mechanism of action in which proteins can be controlled with radio waves. In doing so, they influence a sensitive quantum state known as spin and make it visible via light. In the future, such findings could help detect and even direct biochemical processes in cells simply from the outside using radio waves.

The origin of enigmatic long-period radio bursts has been shown to be from the clash of magnetic fields as a white dwarf steals matter from a close red dwarf star.

In a groundbreaking leap for cardiovascular research, scientists have engineered self-assembled chamber-like cardiac organoids that faithfully mimic the complex architecture and functionality of human heart chambers. This pioneering development not only provides a transformative model for studying cardiac chamber formation but also establishes a robust platform for assessing drug-induced cardiotoxicity, potentially revolutionizing how new therapeutics are evaluated before clinical trials. Published this year in Nature Communications, the work by Zou, Wang, Zheng, and colleagues spotlights the convergence of stem cell biology, tissue engineering, and regenerative medicine, presenting an unprecedented window into the earliest steps of heart development and disease modeling.

The human heart’s intricate structure—comprising multiple chambers each with specialized functions—is notoriously challenging to replicate in vitro. Traditional two-dimensional cardiomyocyte cultures lack the spatial organization and mechanical cues necessary for proper cardiac maturation. While previous three-dimensional cardiac organoids have demonstrated contractile activity and cell heterogeneity, recreating chamber-like structures that resemble true heart morphology has remained elusive. Zou et al. surmount this hurdle by harnessing self-assembly principles, enabling pluripotent stem cells to organize autonomously into defined, chambered organoids. This architectural mimicry is essential, as the heart’s ability to pump blood relies heavily on the precise formation and interplay of distinct chambers.

Central to their approach is the optimization of culture conditions that guide stem cells down specific differentiation trajectories while promoting cellular interactions and biomechanical feedback mechanisms. Through a carefully orchestrated protocol, the research team modulated signaling pathways such as Wnt, BMP, and Notch, which are pivotal during embryonic heart development. This biochemical guidance, combined with tailored extracellular matrix components, facilitated the aggregation of cardiomyocytes, cardiac fibroblasts, and endothelial cells into a cohesive, hollow structure reminiscent of heart chambers. Notably, the organoids exhibited spontaneous contractions with coordinated electrical conduction, underscoring their functional maturity.

This model opens unprecedented avenues for interrogating the molecular and biomechanical determinants of cardiac chamber morphogenesis. Researchers can now probe how gradients of morphogens and mechanical forces sculpt chamber identity, valve formation, and myocardial patterning in a controlled laboratory environment. By recapitulating key developmental milestones in vitro, these organoids provide insight into congenital heart defects and allow for the dissection of complex gene-environment interactions that underlie cardiac malformations. The study paves the way for elucidating pathway-specific perturbations linked to heart disease.

In addition to developmental insights, the chamber-like organoids serve as a sophisticated platform for pharmacological screening. Drug-induced cardiotoxicity remains a pervasive challenge in drug development, often causing late-stage failures or post-market withdrawals. Current preclinical models, including animal testing and 2D cultures, only partially recapitulate human cardiac physiology, limiting predictive accuracy. These self-assembled cardiac organoids, by contrast, provide a human-relevant context to assess the electrophysiological, structural, and contractile effects of novel compounds, capturing subtle toxicities that conventional assays might overlook.

The research team demonstrated the utility of their platform by testing well-known cardiotoxic agents, revealing dose-dependent disruptions in organoid rhythm and contractile force. Their findings correlated with clinical manifestations observed in patients, suggesting that this model can forecast adverse cardiac responses with enhanced fidelity. This capability could streamline drug safety assessments, reduce reliance on animal models, and ultimately expedite the delivery of safer cardiovascular therapeutics to patients.

Crucially, the organoids produced by Zou et al. display remarkable reproducibility and scalability, addressing long-standing challenges in organoid research. By standardizing the self-assembly process, the team ensured consistent formation of chambers exhibiting uniform size, morphology, and cell composition across batches. This consistency lays the groundwork for larger-scale applications such as high-throughput drug screening and precision medicine initiatives, where patient-derived organoids could be tested against personalized therapeutic regimens.

Furthermore, the researchers leveraged advanced imaging and electrophysiological techniques to characterize organoid dynamics in real time. Using high-resolution confocal microscopy and multi-electrode arrays, they mapped calcium transients, electrical propagation, and mechanical contraction patterns within the chamber-like structures. These comprehensive analyses confirmed that the organoids not only structurally resemble heart chambers but also functionally emulate their synchronous beating and electrical coupling, hallmarks of a physiologically relevant cardiac model.

Beyond drug testing, the potential of these cardiac organoids extends into regenerative medicine. The ability to self-organize into chambered constructs suggests their suitability for bioengineered tissue grafts aimed at repairing damaged myocardium. Although clinical translation remains distant, the mechanistic insights gained from these models can inform strategies for enhancing cardiac regeneration, integrating stem cell therapies, and engineering next-generation heart patches.

Zou and colleagues also touched upon the ethical and logistical advantages of their organoid system. By reducing dependence on animal experimentation, their model aligns with the principles of the 3Rs (replacement, reduction, refinement) in biomedical research. Additionally, the use of human induced pluripotent stem cells enables studies on genetically diverse populations, enhancing our understanding of how individual genetic backgrounds influence heart development and drug responses.

The combination of bioengineering, developmental biology, and pharmacology embodied in this research illustrates a paradigm shift in cardiovascular science. Where once the heart was an impenetrable black box, the creation of chamber-like cardiac organoids offers a tangible window into its formation, function, and pathologies. This synthetic heart tissue platform promises to accelerate the discovery of novel treatments for heart disease, a leading cause of mortality worldwide, with profound implications for public health.

Looking forward, the research sets the stage for integrating other cell types critical to heart function, such as immune cells and specialized conduction system components, to achieve even more physiologically comprehensive organoids. Advances in microfluidics and tissue perfusion could further enhance nutrient delivery and waste removal, mimicking in vivo conditions and prolonging organoid survival. Such innovations will push the boundaries of what organoids can reveal about cardiac biology and therapeutic potential.

In summary, the self-assembled chamber-like cardiac organoids developed by Zou et al. represent an extraordinary technological and conceptual advance. By recapitulating the form and function of human cardiac chambers in vitro, they provide a powerful tool for unraveling the complexities of heart development and disease, enabling safer drug discovery, and opening new horizons for regenerative therapies. This landmark study heralds a new era in cardiovascular research where the heart’s mysteries can be explored with unprecedented clarity, precision, and relevance.

---

Subject of Research: Cardiac development, cardiac organoids, cardiotoxicity assessment, tissue engineering.

Article Title: Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment.

Article References:
Zou, X., Wang, F., Zheng, H. et al. Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73822-6

Image Credits: AI Generated

In a groundbreaking clinical exploration poised to redefine neonatal care, researchers have unveiled the potential of citrate-functionalized manganese oxide nanoparticles as a novel intervention for infants at risk of acute bilirubin encephalopathy (ABE). This phase 1 observational trial, recently published in Pediatric Research, marks a pioneering stride in nanomedicine’s application to one of the most vulnerable patient populations—newborns born at or beyond 35 weeks of gestation.

Acute bilirubin encephalopathy, a severe neurological condition resulting from elevated levels of unconjugated bilirubin in the blood, underscores a significant challenge in neonatology. Traditional therapeutic paradigms such as phototherapy and exchange transfusion are effective yet fraught with limitations, including logistical complications and risks of invasive procedures. The introduction of manganese oxide nanoparticles, meticulously functionalized with citrate to enhance biocompatibility and targeting ability, presents a promising alternative grounded in cutting-edge nanotechnology.

Manganese oxide nanoparticles stand out due to their intrinsic catalytic and antioxidative properties. When functionalized with citrate molecules, these nanoparticles acquire enhanced solubility and stability in physiological environments, alongside potential to interact specifically with biological targets related to bilirubin metabolism. This innovative functionalization not only mitigates the inherent toxicity risks associated with metal oxides but also amplifies the therapeutic index by promoting controlled endogenous reactive oxygen species modulation.

The trial enrolled neonates meeting stringent inclusion criteria—those born at 35 weeks gestation or later and identified to be at imminent risk of developing ABE based on serum bilirubin levels and clinical parameters. This focused cohort allowed for precise evaluation of safety, tolerability, and preliminary efficacy without exposing extremely preterm or otherwise vulnerable neonates to investigational risks prematurely.

Detailed pharmacokinetic profiling revealed a favorable biodistribution pattern of the citrate-functionalized manganese oxide nanoparticles, with key accumulation in hepatic and neural tissues critical to bilirubin processing and neuroprotection. Importantly, systemic clearance rates aligned with safety expectations, showcasing significant degradation and elimination within a clinically acceptable window, reducing concerns about long-term nanoparticle persistence.

Safety endpoints constituted the cornerstone of this phase 1 study. Neonates received carefully calibrated doses of the nanoparticle formulation under rigorous monitoring for adverse events, hematologic parameters, and hepatic function. Encouragingly, no serious adverse reactions or biochemical disturbances attributable to the nanoparticles surfaced, reinforcing the therapeutic promise while confirming initial safety profiles essential for subsequent trial phases.

Mechanistic insights gleaned from translational assays indicated that the nanoparticles exert their effects through catalytic degradation pathways that enhance bilirubin clearance. By facilitating redox cycling and promoting enzymatic conversion within hepatic microsomes, the citrate-functionalized manganese oxide particles appear to attenuate serum bilirubin concentrations, thereby curtailing the risk of neurotoxicity that characterizes ABE.

Moreover, preliminary neuroprotective effects inferred from biomarker analyses and neuroimaging modalities hinted at the nanoparticles’ ability to mitigate oxidative stress and neuronal inflammation—both critical in ABE pathogenesis. These findings pave the way for not only preventing bilirubin-induced neurotoxicity but also fostering neural resilience during the delicate postnatal period.

This paradigm-shifting approach stands at the intersection of materials science, nanotechnology, and neonatology, symbolizing a new frontier where nanoscale interventions could supplant or synergize with existing modalities. The multidisciplinary collaboration that propelled this research reflects the concerted global efforts to address longstanding pediatric health challenges through innovative technological lenses.

While these initial findings validate the feasibility and safety of citrate-functionalized manganese oxide nanoparticles in a high-risk neonatal population, the research community anticipates larger, randomized controlled trials to robustly ascertain therapeutic efficacy and inform clinical guidelines. The scalability of nanoparticle synthesis, standardization of dosing regimens, and long-term outcome monitoring remain critical next steps before widespread adoption.

Intriguingly, the nanoparticles’ customizable surface chemistry opens avenues for conjugation with targeting ligands or drug molecules, potentially transforming this platform into a versatile vehicle for delivering adjunct therapies. The adaptability inherent to nanoparticle engineering could revolutionize how clinicians manage a spectrum of neonatal conditions beyond hyperbilirubinemia, broadening the horizon of precision neonatology.

Ethical considerations rigorously guided this trial design, emphasizing transparency with parents and guardians, meticulous risk-benefit assessments, and adherence to pediatric research regulations. This conscientious approach underscores the importance of safeguarding the delicate neonatal demographic while advancing medical frontiers responsibly.

From a translational standpoint, the synthesis of citrate-functionalized manganese oxide nanoparticles employed scalable green chemistry methods, emphasizing sustainability and minimizing environmental impact—factors increasingly integral to biomedical innovation in the 21st century. This methodology may serve as a template for manufacturing other functional nanomaterials destined for clinical applications.

The societal implications of this research ripple beyond the scientific community. Acute bilirubin encephalopathy remains a preventable cause of neonatal morbidity and mortality, disproportionately affecting low-resource settings. The development of an effective, safe, and potentially cost-efficient nanoparticle-based therapy could dramatically alleviate healthcare burdens, reduce long-term disabilities, and improve quality of life for countless children worldwide.

Scientific enthusiasm surrounding this breakthrough is palpable, with experts lauding the seamless integration of nanotechnology and neonatal medicine as a testament to the transformative power of interdisciplinary research. The phase 1 observational trial’s results catalyze a new era, inspiring further exploration into nanomaterials tailored for pediatric therapeutics where unmet clinical needs abound.

As clinicians, researchers, and policymakers digest these compelling outcomes, the message is clear: the marriage of nanoscience and neonatology is yielding tangible hope for conditions once deemed intractable. Citrate-functionalized manganese oxide nanoparticles epitomize not only scientific ingenuity but also the unwavering commitment to safeguarding life’s earliest moments through pioneering care.

Subject of Research:

Article Title:

Article References:
Mallick, A.K., Dutta, T., Hauli, R. et al. Citrate-functionalized manganese oxide nanoparticles in neonates ≥35 weeks gestation at risk of acute bilirubin encephalopathy: a phase 1 observational trial. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05144-8

Image Credits: AI Generated

DOI: 02 June 2026

Keywords:

In the endless quest to unravel the mysteries of Mars, a landmark study has emerged proposing groundbreaking criteria to identify the elusive lower crust and mantle materials of the Red Planet. This pioneering research, spearheaded by Trowbridge, Horgan, Weiss, and colleagues, focuses on the geological aftermath of the colossal Isidis impact basin, a feature that has long intrigued planetary scientists due to its immense scale and unique compositional context. Published in Communications Earth & Environment, their work sets a new standard for interpreting Martian geology by delineating precise identification markers for the Martian subsurface layers that have been thrust upward by ancient impact processes.

The Isidis Planitia, a vast impact basin approximately 1500 kilometers in diameter, represents one of the youngest and most prominent geological structures on Mars. Formed around 3.9 billion years ago during the Late Heavy Bombardment, this crater provides a natural window into the planet’s interior through the excavation and exposure of its lower crust and potentially mantle materials. The research team capitalized on this unique feature, utilizing high-resolution spectral data, geophysical modeling, and comparative analysis to develop robust criteria for differentiating deep crustal and mantle rocks from more common surface deposits.

Central to the study is the integration of multispectral imaging from orbiters such as Mars Reconnaissance Orbiter’s CRISM instrument and detailed geochemical simulations. These tools enable the extraction of compositional signatures associated with varying mineral assemblages. For instance, the presence of olivine-dominated ultramafic rocks, distinct pyroxene compositions, and specific alteration minerals serve as key indicators for mantle-derived materials. By correlating these spectral indicators with geophysical anomalies detected in the region, the team crafted a comprehensive framework to pinpoint probable lower crust and mantle exposures.

One of the study’s remarkable achievements is the identification of an unexpected diversity in the mineralogical assemblage within the Isidis excavated materials. Contrary to previous models that predicted a relatively uniform lower crustal layer, the researchers found evidence suggesting significant heterogeneity. This includes variations in Mg/Fe ratios within olivine crystals and compositional differences in pyroxenes, which hint at complex magmatic differentiation and mantle metasomatism events that predate the impact. These findings challenge conventional wisdom and suggest that Mars’s deep interior retains a more dynamic and chemically intricate history than once thought.

The implications of correctly identifying lower crust and mantle materials extend far beyond academic interest. These rocks act as a geological archive, preserving records of early planetary differentiation, mantle convection patterns, and volcanic activity. Unlocking these secrets helps refine models of Mars’s thermal evolution and provides insights into its tectonic and volcanic history. Moreover, such knowledge is vital for astrobiological considerations; the geochemical environment of the lower crust and mantle potentially harbors clues about past habitability and subsurface water reservoirs.

The methodology outlined in this paper is also a leap forward in planetary remote sensing. Previous approaches often relied solely on surface morphologies or broad compositional classifications that were insufficiently discriminating to distinguish deep crustal from upper crustal materials. By employing an interdisciplinary strategy that includes spectral characterization, petrological modeling, and impact excavation dynamics, the authors have set a new benchmark for planetary geoscience research. This approach has wide applicability, opening pathways to reassess other Martian regions and potentially the crust-mantle interface of other terrestrial bodies like the Moon or Mercury.

Crucially, the authors address the complexity of impact processes themselves and their influence on exposing and altering the crust-mantle interface. The Isidis impact, due to its scale and the kinetic energy involved, likely caused widespread fracturing and melting, modifying the original signatures of deep-seated rocks. Disentangling these effects required sophisticated modeling of shock metamorphism and ejecta redistribution, ensuring that identified materials can be confidently traced back to their sources within the planetary interior rather than being artifacts of impact mixing.

This research also propels forward the discourse on Mars sample return missions. Identifying locations where lower crust and mantle materials are exposed at the surface highlights prime sampling sites for future missions. These samples could revolutionize our understanding of the Red Planet’s formation and development. The criteria provided by Trowbridge et al. serve as a guide to prioritize landing sites that maximize the scientific return by targeting the most geologically informative materials.

Furthermore, the study confronts challenges associated with remote geochemical analysis on Mars. Variability in dust cover, surface weathering, and the presence of secondary minerals have historically confounded interpretations. The authors mitigate these issues through a multi-layered approach combining spectral deconvolution, thermal inertia data, and comparative terrestrial analog studies. This layered methodology enhances confidence in the identification of primary crustal and mantle signatures amid surface contaminants, elevating the precision of remote geological investigations.

The impact on planetary geology education and public engagement cannot be overstated. The clarity and innovation demonstrated in this research provide a compelling narrative about Mars’s inner workings and cataclysmic past. Communicating such advances in an accessible yet scientifically rigorous manner enriches both academic discourse and public understanding, inspiring the next generation of planetary scientists and enthusiasts worldwide.

Looking ahead, the authors emphasize the need for corroborative in-situ investigations to validate their proposed identification framework. Landers and rovers equipped with advanced geochemical and mineralogical tools can directly test these hypotheses by sampling targeted outcrops within and around Isidis Planitia. Collaborative efforts between orbital reconnaissance and landed operations will be essential to fully unravel the formation processes and compositional diversity of Mars’s lower crust and mantle.

Another noteworthy dimension of the study is the potential influence of these deep Martian materials on surface volcanism and tectonics. By better characterizing the elemental and mineralogical makeup of the lower crust and mantle, scientists can improve models of mantle melting and magmatic ascent, which shape volcanic constructs observed across Mars. This understanding bridges the gap between subsurface processes and planetary surface evolution, providing a holistic view of Martian geodynamics.

In the broader context of comparative planetology, this work echoes studies of Earth’s lower crust and mantle, drawing parallels and contrasts that elucidate planetary formation mechanisms and divergence. Differences observed in Martian deep crustal rocks versus Earth’s geology underscore the unique pathways planetary interiors can take under varying thermal and compositional regimes. Such insights refine theoretical frameworks applicable across our Solar System’s terrestrial planets.

The study also invites re-examination of the isotopic and age data from Martian meteorites believed to originate from deep crustal or mantle sources. Integrating these data with the newly established identification criteria enhances confidence in meteorite provenance assignments and contributes to more nuanced timelines of Martian geological history.

In summation, the comprehensive criteria proposed for identifying the Martian lower crust and mantle excavated by the Isidis impact constitute a transformative leap in understanding the Red Planet’s subsurface architecture. This research lays the groundwork for future exploration, sample return, and comparative geological studies, propelling Mars science into a new era of detail and discovery. As humanity continues its exploration of Mars, such foundational work illuminates the path toward deciphering the planet’s complex past and its potential for harboring life.

---

Subject of Research: Identification criteria for Martian lower crust and mantle materials excavated by the Isidis impact.

Article Title: Proposed identification criteria of the Martian lower crust and mantle excavated by the Isidis impact.

Article References:
Trowbridge, A.J., Horgan, B., Weiss, B.P. et al. Proposed identification criteria of the Martian lower crust and mantle excavated by the Isidis impact. Commun Earth Environ (2026). https://doi.org/10.1038/s43247-026-03617-6

Image Credits: AI Generated

The Trump administration is dismantling a $368 million deep-ocean observation system that monitors marine ecosystems and the effects of climate change.

The Trump administration is dismantling a $368 million deep-ocean observation system that monitors marine ecosystems and the effects of climate change.

© National Science Foundation Ocean Observatories Initiative

From sizzling bacon in the kitchen to wildfire smoke in the sky, cooking and pollution release microscopic particles that affect humans' health, the air they breathe, and even weather and climate. New research from Virginia Tech is poised to upend how scientists think about the structure of these tiny airborne droplets and what that means for predictions around air quality, pollution spread, and climate models.

Uma condição capaz de mudar a vida em poucos minutos acaba de ganhar atenção especial das autoridades internacionais de saúde. O acidente vascular cerebral (AVC) foi colocado entre as prioridades globais pela Organização Mundial da Saúde (OMS), que defende ações mais amplas para reduzir o número de mortes e sequelas provocadas pela doença.

A preocupação é sustentada por números expressivos. Nas últimas duas décadas, a probabilidade de uma pessoa sofrer um AVC ao longo da vida aumentou significativamente. Diante desse cenário, especialistas alertam que a prevenção e o reconhecimento rápido dos sintomas podem ser decisivos para salvar vidas e preservar funções cerebrais.

Uma doença que continua avançando silenciosamente

Muitas pessoas associam o AVC apenas a idosos, mas a realidade é mais ampla. Estimativas atuais indicam que cerca de 25% dos adultos poderão sofrer um AVC ao longo da vida.

Dados globais apontam que o AVC esteve relacionado a milhões de casos em 2021, consolidando-se entre as principais causas de incapacidade e mortalidade no planeta. Esse crescimento tem mobilizado governos, hospitais e organizações de saúde em busca de estratégias mais eficientes para reduzir seu impacto.

Além das consequências imediatas, o AVC frequentemente gera limitações físicas, cognitivas e emocionais que podem acompanhar o paciente por muitos anos.

O que acontece quando o cérebro deixa de receber sangue?

Para desempenhar suas funções corretamente, o cérebro precisa receber oxigênio e nutrientes de forma constante. Quando esse suprimento é interrompido, células cerebrais começam a sofrer danos em questão de minutos.

Existem duas formas principais da doença:

• AVC isquêmico, causado pelo bloqueio da circulação sanguínea.
• AVC hemorrágico, provocado pelo rompimento de um vaso cerebral.

Independentemente da causa, a rapidez no atendimento influencia diretamente as chances de recuperação.

Sinais que exigem ação imediata

Reconhecer os sintomas precocemente pode reduzir complicações graves.

Entre os principais sinais estão:

• Fraqueza repentina em um lado do corpo
• Dificuldade para falar
• Alterações súbitas da visão
• Perda de equilíbrio
• Dormência em braços, pernas ou rosto
• Confusão mental inesperada

Ao perceber qualquer um desses sintomas, a recomendação é procurar assistência médica sem demora.

A recuperação vai muito além da emergência

O tratamento do AVC não termina quando o paciente deixa a unidade de emergência. Em muitos casos, a fase de recuperação exige acompanhamento especializado durante semanas ou meses.

O processo pode envolver:

• Fisioterapia
• Fonoaudiologia
• Terapia ocupacional
• Acompanhamento neurológico
• Suporte psicológico

Esse cuidado contínuo busca restaurar funções perdidas e melhorar a autonomia do paciente nas atividades do dia a dia.

A prevenção ainda é a melhor estratégia

Embora o AVC seja uma condição grave, muitos fatores associados ao seu desenvolvimento podem ser controlados. Hipertensão, diabetes, colesterol alto, obesidade, cigarro e falta de atividade física estão entre os fatores que podem aumentar o risco de AVC e que podem ser controlados. 

Por esse motivo, a resolução aprovada pela OMS destaca a necessidade de ampliar campanhas educativas, fortalecer os sistemas de saúde e investir em diagnóstico rápido e tratamento especializado.

À medida que o número de casos cresce em diferentes regiões do mundo, especialistas consideram que agir antes do surgimento da doença continua sendo a medida mais eficaz para reduzir mortes, sequelas e o impacto do AVC na população.

Chemical traces preserved in ancient rocks indicate that marine environments were deteriorating long before the catastrophe that wiped out vast numbers of species at the end of the Triassic period, around 201 million years ago.

The post Ancient Oceans Began Losing Oxygen Millions of Years before End-Triassic Mass Extinction appeared first on Sci.News: Breaking Science News.

Michael Shaulov, CEO of Fireblocks, joins Scarlet Fu and Tim Stenovec on "Bloomberg Crypto." Fireblocks, the crypto infrastructure company launched Fireblocks Flow today as part of the Money 20/20 conference in Amsterdam. (Source: Bloomberg)

Microsoft has been deeply committed to the growth of generative AI technology in recent years through its now-fragmented partnership with OpenAI. At Build 2026, the company remains all-in on AI, and it's looking toward the future with a new software platform. The new Android-based OS is called Project Solara, and Microsoft says Solara is designed to run agents instead of apps.

Project Solara is not something you'll have to worry about killing your apps anytime soon. It's limited to a few pieces of concept hardware and software that are awaiting the magical agents of the future. The vision is for Solara to run on myriad specialized devices with interfaces generated on the spot, and it's all powered by the explosive intelligence of models that Microsoft and others insist will soon exist.

According to Microsoft, Solara is a chip-to-cloud platform intended to free agents from reliance on single interfaces. Much of Microsoft's messaging around AI is speculative and self-serving, but the company rightly points out that new computing form factors have always required specialization, and that process is complex and expensive. The shift to mobile computing, for example, tripped Microsoft up multiple times as it fell behind on app availability, security, and long-term support.

Read full article

Comments

© Microsoft

In a groundbreaking development poised to revolutionize neonatal care and reproductive technologies, the emerging field of artificial womb (AW) technology has sparked intense debate among scientists, ethicists, and policymakers. As researchers publish comprehensive scoping reviews that delve into the layered ethical considerations surrounding this cutting-edge technology, it becomes evident that the future of human gestation may soon transcend traditional biological boundaries, raising profound questions about the nature of life, parenthood, and medical intervention.

Artificial wombs, also known as ectogenesis devices, are engineered life-support systems designed to mimic the biological functions of the uterus, allowing premature or otherwise vulnerable fetuses to develop in an artificial environment. Unlike conventional neonatal incubators, artificial wombs aim to recreate the complex physiological conditions that a natural womb provides, including the delivery of oxygen, nutrients, and hormonal signals essential for normal development. This technological innovation holds the potential to dramatically improve survival rates for extremely premature infants, who currently face high risks of mortality and lifelong disability.

Technical strides in AW technology have been propelled by advances in biomaterials, microfluidics, and fetal physiology. Researchers have developed sophisticated bioreactors equipped with synthetic amniotic fluid and artificial placenta interfaces capable of facilitating gas exchange and nutrient delivery while eliminating waste products. These systems simulate the mechanical and chemical environment of the womb, providing a supportive milieu that supports continuous growth and organ maturation. Animal trials have demonstrated promising results, whereby fetal lambs have been maintained inside artificial wombs for several weeks, showing notable development comparable to in utero progression.

Despite these promising advancements, the path to clinical application in humans remains fraught with technical, ethical, and regulatory challenges. One of the critical technical barriers is ensuring the precise control and replication of the uterine environment’s dynamic nature. The uterus is not a static chamber; it orchestrates complex biochemical signaling that influences the fetus’s epigenetic programming, immune system development, and neurocognitive growth. Achieving such a level of biomimicry requires integrating real-time monitoring technologies with adaptive feedback mechanisms, demanding unprecedented interdisciplinary collaboration.

The ethical dimensions introduced by artificial womb technology extend far beyond the scope of conventional neonatal care protocols. Principally, AW technology disrupts conventional understandings of gestation’s biological and social parameters. By decoupling gestation from the maternal body, it challenges the traditional gestational kinship and raises questions about the legal and moral status of the fetus under artificial care. This separation provokes debates over parental rights, responsibilities, and the potential redefinition of motherhood. Furthermore, the prospect of ectogenesis stirs societal concerns regarding reproductive autonomy, inequality, and the commodification of fetal development.

A particularly contentious aspect of artificial womb deployment pertains to the concept of viability—the gestational age at which a fetus can survive ex utero, a legal and medical benchmark for debates on abortion rights and neonatal care decisions. With AW technology potentially lowering the threshold of viability to much earlier gestational stages, this criterion could face unprecedented challenges. Ethical frameworks would need to adapt to the expanded range of survivable gestational ages, potentially reshaping public health policies and reproductive laws worldwide.

Moreover, the ramifications for fetuses with congenital abnormalities or those requiring intensive medical interventions raise critical ethical considerations. Artificial wombs could theoretically preserve and nurture fetuses previously deemed nonviable, complicating decisions about the extent of medical care and quality of life assessments. This possibility calls for robust ethical guidelines balancing the benefits of survival with respect for individual dignity and long-term outcomes.

Privacy and consent issues also loom large in this emerging field. The intimate nature of gestation, traditionally confined within the maternal body, would be externalized and subject to clinical control and technological mediation. This transition demands rigorous protocols to ensure informed consent, data privacy, and the protection of vulnerable subjects in artificial gestation settings. The question arises whether future parents or guardians can fully comprehend the implications of entrusting fetal development to machines, necessitating enhanced counseling and oversight frameworks.

Furthermore, artificial womb technology raises significant social justice concerns. Access to such advanced reproductive technologies may be limited by socioeconomic status, healthcare infrastructure, and geographic location, potentially exacerbating existing disparities in neonatal outcomes. Policymakers must therefore anticipate and address inequities in availability to prevent the widening of healthcare gaps, ensuring that AW benefits are equitably distributed.

From a psychological perspective, the impact on parent-child bonding when gestation occurs outside the maternal womb remains largely unexplored. The intimate physical and hormonal interactions during pregnancy play a pivotal role in maternal-fetal attachment and subsequent family dynamics. The absence of direct gestational involvement may influence parental bonding, emotional well-being, and child development, indicating the need for comprehensive psychological support and long-term studies.

On the regulatory front, global frameworks governing artificial womb technology are nascent and heterogeneous. Establishing consistent guidelines to oversee research, clinical trials, and eventual clinical use will require international cooperation among scientific bodies, bioethicists, and governmental agencies. Regulatory oversight must balance the encouragement of innovation with safeguarding against premature or unethical applications.

Importantly, public perception and societal acceptance will significantly influence the trajectory of artificial womb technology. Public engagement initiatives, transparency in research practices, and inclusive dialogues are essential to fostering trust and understanding. Addressing fears of “unnatural” reproduction and debunking misconceptions will be critical to integrating AW technology into mainstream medical practice sensitively.

As AW research progresses toward clinical reality, multidisciplinary collaboration will be imperative. Biomedical engineers, neonatologists, ethicists, sociologists, and lawmakers must converge to navigate the complex scientific and moral landscape. The responsible development of artificial womb technology entails anticipatory governance that proactively identifies and mitigates risks while amplifying potential benefits.

In conclusion, artificial womb technology represents a paradigm shift with monumental implications for medicine, ethics, and society. While offering hope to improve neonatal survival and reimagine reproductive possibilities, it simultaneously demands careful scrutiny of the profound ethical questions it raises. The journey from experimental prototypes to clinical tools will require deliberate, informed deliberation, ensuring that this revolutionary technology serves humanity’s best interests without compromising foundational values.

As ongoing research continues to unravel the intricacies of artificial gestation, the global community stands at a crossroads. The choices made today will sculpt the future of human reproduction and neonatal care, exemplifying the delicate interplay between scientific innovation and ethical responsibility. The promise of artificial wombs invites us to reconsider not only how life begins but also the societal frameworks that sustain it in an ever-evolving biomedical era.

---

Subject of Research:
Ethical considerations surrounding artificial womb technology and its implications for neonatal care and reproductive medicine.

Article Title:
Correction: Artificial womb technology; a scoping review of ethical considerations.

Article References:
De Bie, F.R., Paul, J., Malek, J. et al. Correction: Artificial womb technology; a scoping review of ethical considerations. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02746-2

Image Credits:
AI Generated

Emerging research casting a critical eye on the widespread use of glyphosate has unveiled concerning links between exposure to this common herbicide and adverse effects on kidney function among agricultural workers in Central America. A groundbreaking cohort study conducted by a team of international scientists has meticulously measured glyphosate levels in urine samples from workers in El Salvador and Nicaragua, revealing a troubling pattern that connects chemical exposure to diminished renal health. The implications of this research extend far beyond the fields where glyphosate is applied, raising urgent questions about occupational safety, environmental health, and public policy surrounding herbicide regulation.

Glyphosate, a widely used organophosphorus herbicide found in countless agricultural products globally, has long been a subject of debate in both scientific and regulatory circles. Used extensively due to its effectiveness in controlling broadleaf weeds and grasses, glyphosate’s pervasive presence in the environment has elicited scrutiny concerning its potential toxicological effects on humans and ecosystems. The latest study approaches this discourse from a rigorous, epidemiological perspective, focusing on populations with the highest likelihood of exposure—the workers involved directly in herbicide application.

The research team undertook a robust cohort analysis, systematically collecting and analyzing urinary glyphosate concentrations from hundreds of agricultural laborers in the two Central American countries. They combined these biomonitoring efforts with comprehensive kidney function assessments, including measurement of biomarkers such as serum creatinine and estimated glomerular filtration rate (eGFR), which serve as indicators of renal performance and health. Through this integrative approach, the investigators sought to elucidate whether the burden of glyphosate accumulates in exposed individuals and if such accumulation correlates with measurable declines in kidney function.

Importantly, the study cohort was composed of workers engaged in diverse agricultural tasks, ranging from field spraying to crop maintenance, thereby encompassing a realistic spectrum of exposure gradients. The investigators incorporated detailed questionnaires addressing work practices, use of protective equipment, duration, and intensity of exposure, which allowed for nuanced statistical modeling of glyphosate’s effect on renal outcomes. This multifaceted methodology ensured that observed associations could be robustly attributed to glyphosate exposure rather than confounded by extraneous variables.

Results demonstrated a clear dose-response relationship whereby higher urinary glyphosate concentrations corresponded to diminished eGFR values, indicating early-stage kidney dysfunction. The findings are particularly alarming given that these renal impairments were detected even in the absence of overt clinical symptoms, suggesting that chronic low-level exposure may silently compromise kidney health over time. The study thus underscores the insidious nature of glyphosate toxicity which may evade detection through standard medical assessments until substantial damage has occurred.

The researchers also highlighted that many affected workers had limited access to proper protective gear or training on safe herbicide use, factors that likely exacerbated their vulnerability. The absence of rigorous occupational safeguards in many agricultural settings in developing nations amplifies the public health risk, potentially creating epidemic-like conditions of chronic kidney disease among farming communities reliant on manual labor. This evidence calls for urgent review and enhancement of worker safety protocols as a preventive measure.

Mechanistically, the study postulates that glyphosate may induce nephrotoxicity through oxidative stress pathways and disruption of renal tubular cells, as suggested by recent toxicological experiments. The herbicide’s interference with mitochondrial function in kidney cells could precipitate cellular injury, inflammation, and fibrosis, ultimately impairing the organ’s filtration capacity. Additional research is warranted to dissect these molecular pathways further, but the current epidemiological data strongly point to glyphosate as a contributing nephrotoxin.

The implications of these findings reverberate globally, considering glyphosate’s ubiquity in modern agriculture and its residues detected in various environmental compartments including water sources and food products. Populations residing near agricultural zones may be subjected to inadvertent exposure, augmenting the need for environmental monitoring and biomonitoring programs. Moreover, regulatory agencies must weigh such emerging evidence in reevaluating permissible exposure limits and enforcing stricter guidelines to protect vulnerable groups.

Public health advocates emphasize that glyphosate-related kidney dysfunction could represent a larger, underrecognized component of the global chronic kidney disease burden, particularly in tropical and subtropical regions where agricultural employment predominates. Interdisciplinary cooperation among nephrologists, toxicologists, epidemiologists, and policymakers is essential to develop targeted interventions, diagnostic strategies, and surveillance frameworks that address this growing epidemic.

Policy responses could include mandatory training for pesticide applicators, distribution of effective personal protective equipment, and the promotion of alternative weed management techniques that reduce reliance on chemical herbicides. These measures would help mitigate exposure risks while balancing agricultural productivity needs. Additionally, expanding healthcare access to early detection and management services for affected populations remains critical.

In summary, the comprehensive cohort study conducted in El Salvador and Nicaragua sheds light on the hidden health toll exacted by glyphosate exposure on kidney function among agricultural workers. The clear correlation between urinary glyphosate levels and subclinical kidney impairment not only advances scientific understanding but also challenges existing paradigms of pesticide safety. This landmark research serves as a clarion call to safeguard the wellbeing of those who labor in the fields and, by extension, the broader communities linked to agricultural production systems worldwide.

Future research trajectories should incorporate longitudinal follow-ups to track renal function trajectories over time, explore gene-environment interactions that influence susceptibility, and evaluate the efficacy of intervention strategies. Only through such concerted efforts can the full scope of glyphosate’s health impacts be comprehended and mitigated, ensuring that food production does not come at the cost of human health.

This study significantly enriches the evidence base informing ongoing debates about glyphosate regulation and underscores the urgent need for integrated policies that harmonize agricultural practices with occupational health imperatives. As glyphosate continues to be a cornerstone of weed management, embedding scientific insights into policymaking constitutes a vital step toward sustainable and just farming systems.

By addressing the silent but serious repercussions of glyphosate exposure on renal health, this research invigorates a critical discourse essential for protecting vulnerable worker populations and maintaining the integrity of public health amid evolving environmental challenges.

Subject of Research: Occupational exposure to glyphosate and its impact on kidney function in agricultural workers.

Article Title: Urine glyphosate levels and kidney function outcomes in a cohort study of workers in El Salvador and Nicaragua.

Article References:
Rodgers, K.M., Fimbres, J., Velázquez, J.J.A. et al. Urine glyphosate levels and kidney function outcomes in a cohort study of workers in El Salvador and Nicaragua. J Exp Sci Environ Epidemiol (2026). https://doi.org/10.1038/s41370-026-00913-3

Image Credits: AI Generated

DOI: 02 June 2026

In the realm of scientific innovation, the Boyce Thompson Institute (BTI) has long been synonymous with groundbreaking research and visionary entrepreneurship. With a history spanning over a century, BTI continues to ignite transformative ideas, propelling advances that resonate well beyond its Ithaca, New York campus. The Institute’s culture of curiosity-driven inquiry and rigorous mentorship has nurtured countless scientists whose work shapes global scientific landscapes. Among its most recent and compelling success stories is PrecizionIQ, an India-based health technology startup that exemplifies the intersection of advanced science and impactful healthcare solutions.

PrecizionIQ, co-founded by Pedro Rodrigues, a BTI alumnus and former postdoctoral researcher, is pioneering a revolutionary approach to prenatal diagnostics. The company’s mission centers on developing a non-invasive, highly accurate, and accessible methodology for early fetal chromosomal abnormality detection. This initiative has the potential to redefine prenatal care paradigms globally, offering earlier and clearer diagnostic insights through a straightforward blood or urine test. Their cutting-edge platform uniquely integrates high-resolution mass spectrometry with artificial intelligence-driven biomarker discovery, pushing the boundaries of existing prenatal screening technologies.

The roots of PrecizionIQ’s innovations trace back to Rodrigues’s formative research experience in the laboratory of Frank Schroeder at BTI. This scientific tutelage instilled a robust foundation in metabolomics and analytical chemistry, crucial for discerning subtle biochemical alterations tied to chromosomal anomalies in expectant mothers. While PrecizionIQ operates independently of BTI, the intellectual rigor and interdisciplinary collaboration cultivated within the Institute have left an indelible mark on the company’s ethos and strategic direction. This synergy underscores the enduring impact of academic research institutions on startup ventures aimed at real-world problem solving.

Recently, PrecizionIQ garnered significant acclaim by securing the top startup accolade at the PanIIT Bangalore Summit 2026. This prestigious recognition awarded the company the sought-after “Golden Ticket” to feature in Bharat Ke Super Founders, an Amazon series spotlighting India’s foremost deep-tech innovators. This milestone not only celebrates the company’s technological prowess but also highlights the vibrant ecosystem nurturing frontier scientific endeavors in India. Such platforms amplify the visibility of innovative startups, facilitating broader dissemination and adoption of revolutionary health technologies.

The scientific foundation of PrecizionIQ is deeply innovative. Employing mass spectrometry, the technology profiles maternal metabolic markers with unparalleled resolution, identifying nuanced biochemical shifts indicative of chromosomal disorders such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), Turner syndrome, and Klinefelter syndrome. By capturing these physiological signatures as early as six weeks into pregnancy, the technology promises to revolutionize prenatal genetic screening by offering early, actionable information without the risks associated with invasive procedures like amniocentesis or chorionic villus sampling.

Furthermore, the implementation of AI algorithms fortifies biomarker analysis, enabling the discernment of complex metabolic patterns unrecognizable through traditional diagnostic means. This AI-enhanced biomarker discovery facilitates higher specificity and sensitivity in fetal risk assessments, reducing false positives and inconclusive results that often incite anxiety among expectant parents. The integration of data science with metabolomics manifests a new frontier in clinical diagnostics, paving the way for personalized, non-invasive prenatal care tailored to diverse populations, including those in resource-limited regions.

BTI’s influence extends beyond scientific training to fostering long-standing professional mentorship and collaborative networks, as evidenced by the ongoing involvement of former BTI faculty and staff in PrecizionIQ’s advisory team. Murli Manohar, a former BTI researcher, serves as a scientific and operational advisor, while emeritus professor Daniel Klessig, with his extensive background in BTI’s research environment, provides strategic insights. These enduring partnerships highlight how academic institutions can be vital incubators for sustained innovation, blending technical expertise with entrepreneurial acumen.

At its core, PrecizionIQ embodies a commitment to democratizing prenatal healthcare. The startup recognizes the disparities inherent in current prenatal diagnostic practices, which are often invasive, costly, or logistically unavailable in many parts of the world. By devising a scalable, non-invasive blood or urine-based test accessible at home, the company envisions bridging this gap, making early fetal health risk assessment universally attainable. This objective aligns with a broader global health ethos that prioritizes equity, early intervention, and precision medicine.

The company’s work carries a profoundly human dimension, driven by an acute awareness of the emotional and psychological toll ambiguous prenatal results impose on families. By delivering clearer, earlier diagnoses, PrecizionIQ aims to alleviate uncertainty and foster peace of mind during a critical period of pregnancy. This emphasis on patient-centric benefits underscores the transformative potential of scientific innovation when paired with compassionate healthcare frameworks.

Beyond its immediate technological ambitions, PrecizionIQ represents a testament to the power of interdisciplinary collaboration. The convergence of expertise in metabolomics, analytical chemistry, AI, and clinical medicine creates a robust platform capable of tackling complex biological questions. Such convergence is crucial in addressing multifaceted healthcare challenges, signifying a shift towards integrated research methodologies that transcend traditional disciplinary boundaries.

Looking ahead, PrecizionIQ plans to launch its pioneering prenatal risk test product in 2027. This upcoming release will mark a significant advancement in prenatal diagnostic capabilities and introduce a new standard for early, accessible fetal health screening globally. The anticipated product launch is poised to stimulate continued research and innovation, inspiring further technological advancements in prenatal care and beyond.

The journey of PrecizionIQ from a laboratory concept to an internationally recognized deep-tech startup highlights the potent role of academic alumni networks and cross-institutional mentorship in fostering successful scientific entrepreneurship. The collaboration among former BTI members and founders underscores how sustained academic relationships can translate into impactful innovations with global health implications.

In sum, PrecizionIQ’s evolution exemplifies the symbiotic relationship between cutting-edge scientific research and entrepreneurial vision. Fueled by BTI’s legacy of fostering curiosity, rigorous training, and interdisciplinary problem-solving, the company is poised to revolutionize prenatal diagnostics. As it moves toward commercial deployment, PrecizionIQ stands at the vanguard of a health technology movement striving to deliver earlier, more reliable, and more equitable prenatal testing worldwide, embodying the profound societal impact that science, mentorship, and innovation can jointly achieve.

---

Subject of Research: Development of non-invasive prenatal diagnostic tests using metabolomics and AI-enhanced biomarker discovery.

Article Title: From Laboratory Insight to Global Health Innovation: PrecizionIQ’s Revolutionary Leap in Prenatal Diagnostics

News Publication Date: 2026

Web References:

• PrecizionIQ Official Website: https://precizioniq.com/
• PanIIT Organization: https://www.paniit.org/

Image Credits: PrecizionIQ